Boehringer Ingelheim

For HCPs in the UK and Ireland only. This post has been developed in collaboration with, and funded by, Boehringer Ingelheim. References available via the linked resource below. We wouldn't do a cardiovascular disease review without a blood pressure reading. So why do we do them without a uACR? Sometimes we come across data so stark that it makes you stop and think – how can we do better in our clinical practice? 66% of adults with recorded hypertension in England did not receive a uACR test in the last 12 months preceding December 2025 [Data extracted from CVDPrevent; accessed at: https://lnkd.in/di3xrbEy]. CKD isn't just a kidney problem, it is a cardiovascular problem! People with CKD are 6x more likely to experience a major cardiovascular event and are more likely to die from a heart attack or stroke than ever reaching end-stage renal disease (Based on Greater Manchester data) [Boehringer Ingelheim. Data on file. CRM 2-131025]. Albuminuria, measured by a urine ACR test, is an independent cardiovascular risk marker. Even modest rises can be associated with dramatically higher CV risk, including a 69% increased risk of CV disease [Xia et al, Int J Clin Exp Med 2015]. And it can signal damage to the structure of the kidneys way before eGFR has moved at all. The uACR test is simple. It's cheap and it requires little more than the right bottle to collect it in. When interpreted alongside clinical assessment, eGFR and other established cardiovascular risk factors, uACR identifies people with or at risk of kidney damage earlier, enables better risk stratification, and informs timely use of evidence-based therapies that can slow progression and reduce CV risk in accordance with current clinical guidance. Yet, despite all our guidelines recommending testing, the majority of patients with hypertension are being missed, meaning we can’t know for sure just how high their cardiovascular risk is… We can do better. uACR should be part of every cardiovascular review. 👇 Watch the video and click on the link below for more. And if this resonates, share it. Let's get the word out there and let’s get testing. https://lnkd.in/dc-pFrWg NP-GB-107940 v2 | October 2026

When kidney filters are damaged, a protein called albumin leaks into the urine. This leakage signals widespread inflammation that can damage the heart and brain, increasing the risk of heart attack and stroke. Through Detect the SOS, we're working with partners to make sure this signal doesn't go unnoticed. A simple urine test can help detect this warning sign early. The urine albumin-to-creatinine ratio (uACR) test is a quick, simple way to identify this risk, especially for people living with type 2 diabetes or high blood pressure. 🎥 Watch Dr Neerja Balachander, Vice President for US Clinical Development Medical Affairs, Cardiovascular-Renal-Metabolism at Boehringer Ingelheim, discuss the importance of uACR testing at the Foreign Policy Health Forum. #DetectTheSOS #uACR #HeartHealth #KidneyHealth #GlobalHealth #UNGA81

Heb jij ooit het einde van een regenboog bereikt? 🌈 Afgelopen weekend heb ik het geprobeerd. Samen met Emma Hodel, Eva Leemkuil, Lori Gustafson en Lars van Putten fietsten wij voor Team Boehringer Ingelheim 500 kilometer van Zoutkamp naar Zoutelande tijdens de Coast2Coast Challenge van de Nierstichting. We kregen zo'n beetje alle Nederlandse weersomstandigheden cadeau: zon, regen, héél veel regen, en af en toe een prachtige regenboog. Na een nacht fietsen, weinig slaap en 500 kilometer in de benen was ik eerlijk gezegd best blij dat ik weer gewoon van mijn fiets af mocht stappen. Voor ons was dit een sportieve uitdaging van één weekend. Voor mensen met een nierziekte zijn behandelingen, beperkingen en onzekerheden vaak onderdeel van het dagelijks leven. Juist daarom ben ik trots op wat we samen hebben gedaan. Dankzij alle deelnemers, vrijwilligers, supporters, sponsors en donateurs haalde de Nierstichting dit jaar meer dan €280.000 op voor onderzoek en innovatie die kunnen bijdragen aan een betere toekomst voor nierpatiënten. Een groot compliment aan de Nierstichting voor de organisatie van dit bijzondere evenement. En dank aan Boehringer Ingelheim, trotse hoofdsponsor, voor de steun aan een initiatief dat letterlijk en figuurlijk mensen in beweging brengt. En de regenbogen? Soms zit de pot goud niet aan het einde van de regenboog, maar in wat je samen onderweg bereikt. Dank aan iedereen die heeft gedoneerd, aangemoedigd of meegeleefd. Jullie maakten de kilometers een stuk lichter. Welke uitdaging heb jij ooit onderschat, maar achteraf voor geen goud willen missen? #Coast2Coast #Nierstichting #BoehringerIngelheim #CyclingForACause #Niergezondheid

Obesity is a complex, chronic disease that requires a broader view of health than weight alone. Alina's experience highlights why access to the right support, expertise and care can make a meaningful difference for people living with obesity. #LifeForward

The next breakthrough may begin with a signal hidden in the biology of the tumor. Identifying what is specific to cancer cells, and what distinguishes them from healthy tissue, is central to developing more precise investigational approaches. In small cell lung cancer (SCLC) and extrapulmonary neuroendocrine carcinoma (epNEC) research, Delta-like ligand 3 (DLL3) is one biomarker being studied for its potential to inform more targeted approaches to care.

Test before you treat. Every cancer is unique. Understanding a tumor’s molecular profile can provide valuable insights into the biological factors driving a disease. HER2 (ERBB2) mutations, for example, are genetic alterations that can cause uncontrolled cell growth and contribute to cancer progression in some people with non-small cell lung cancer (NSCLC). Comprehensive biomarker testing at diagnosis can help uncover actionable alterations, support more informed treatment decisions, and help ensure important information is available when it matters most. Make comprehensive biomarker testing part of every diagnostic pathway.